文章摘要
刘兴,况显凤,杨毅,周杨.恩格列净治疗老年2型糖尿病合并冠心病患者的糖代谢效果及心功能的影响[J].老年医学与保健,2025,31(3):705-709
恩格列净治疗老年2型糖尿病合并冠心病患者的糖代谢效果及心功能的影响
Effects of empagliflozin on glucose metabolism and cardiac function in elderly patients with type 2 diabetes mellitus complicat-ed with coronary heart disease
  
DOI:10.3969/j.issn.1008-8296.2025.03.017
中文关键词: 老年  2型糖尿病  冠心病  二甲双胍缓释片  恩格列净  心功能
英文关键词: elderly  type 2 diabetes mellitus  coronary heart disease  metformin sustained-release tablet  empagliflozin  cardiac function
基金项目:2021TG51:四川省医学会伤口疾病(泰阁)专项科研课题
作者单位
刘兴 宜宾市第三人民医院内分泌代谢科 
况显凤 宜宾市第三人民医院呼吸与危重症医学科 
杨毅 四川省医学科学院·四川省人民医院内分泌科 
周杨 宜宾市第三人民医院心血管内科 
摘要点击次数: 168
全文下载次数: 38
中文摘要:
      目的 通过对2型糖尿病合并冠心病老年患者应用恩格列净,探讨此药对该疾病的治疗效果.方法 回顾性分析2022年2月—2024年2月于宜宾市第三人民医院就诊的2型糖尿病合并冠心病老年患者的临床资料.其中观察组(55例)采用恩格列净联合琥珀酸美托洛尔缓释片治疗,对照组(51例)采用二甲双胍缓释片联合琥珀酸美托洛尔缓释片治疗.记录2组患者治疗期间不良反应;比较治疗前及治疗6个月后其糖代谢指标、胰岛及心功能相关指标.结果 治疗6个月后,观察组糖代谢指标值、HOMA-IR均低于对照组(P<0.05);HOMA-β水平均高于对照组(P<0.05).2组患者心功能相关指标值、不良反应发生率组间比较均无统计学差异(P>0.05).结论 恩格列净对2型糖尿病合并冠心病老年患者血糖控制效果较佳,有助于改善患者胰岛及心功能,具有一定的临床应用价值.
英文摘要:
      Objective To explore the therapeutic effect of empagliflozin on elderly patients with type 2 diabetes mellitus(T2DM)complicated with coronary heart disease(CHD).Methods The clinical data of elderly patients with T2DM compli-cated with CHD treated in Third People's Hospital of Yibin City between February 2022 and February 2024 were retrospectively analyzed.The observation group was treated with empagliflozin combined with metoprolol succinate sustained-release tablets(55 cases),while the control group was treated with metformin sustained-release tablet combined with metoprolol succinate sustained-release tablets(51 cases).Adverse reactions during treatment were recorded in both groups.Glucose metabolism in-dices,pancreatic islet function indices,and cardiac function indices were compared before treatment and after 6 months of treat-ment.Results After 6 months of treatment,the levels of glucose metabolism indicators and HOMA-IR in the observation group were significantly lower than those in the control group(P<0.05),while the HOMA-β was significantly higher than that in the control group(P<0.05).There were no significant differences in cardiac function-related indicators and incidence of adverse reactions between the two groups(P>0.05).Conclusion Empagliflozin has a good effect on blood glucose con-trol in elderly patients with T2DM complicated with CHD,and it is helpful to improve the islet and cardiac function of patients,with certain clinical application value.
查看全文   查看/发表评论  下载PDF阅读器
关闭